Possible KRAS downstream target for pancreatic cancer therapy identified

A protein called GSK-3 alpha may promote oncogenic KRAS function, according to first evidence in a new study. Inhibiting GSK-3 in a model of pancreatic tumors yielded a strong anti-tumor response, thus offering a potential therapeutic option.

While the mutated KRAS oncogene is associated with many cancers, it has not yet been successfully targeted by a therapeutic agent. This study is an effort to find another way to target the gene by blocking signals from another protein downstream.

“GSK-3 promotes activity of a protein called NF-kappa B. Our lab has been studying NF-kappa B for a number of years and has published that this protein is important in KRAS signaling. But how KRAS activates NF-kappa B has not been well understood. We have found a link,” said study senior author Albert S. Baldwin, PhD, of the University of North Carolina Lineberger Comprehensive Cancer Center in Chapel Hill.

GSK-3 has alpha and beta forms. The beta form, which has been studied previously, is considered a tumor suppressor. GSK-3 alpha was considered redundant to GSK-3 beta, but the research team found that GSK-3 alpha has a different function than GSK-3 beta. Their studies were done in mice with human pancreatic tumors.

"Our data suggest that GSK-alpha is really an onco-protein and that KRAS utilizes GSK-alpha to activate both NF-kappa B pathways, called canonical and noncanonical. This finding is important because GSK-3 alpha sits on top of the two pathways and inhibits them both, thus making it a viable therapeutic target. We are conducting further pharmacologic studies," said Baldwin. The study was published in Cancer Discovery (2013; doi: 10.1158/2159-8290.CD-12-0541).
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs